Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China

Fineline Cube Aug 13, 2026
Company Deals

Allist Pharmaceuticals Secures Exclusive Greater China License for ArriVent’s Bispecific ADC AST12608/ARR-002

Fineline Cube Aug 13, 2026
Company Deals

Kintor Pharmaceutical Grants Wellrise Exclusive Distribution Rights for KT-939 Raw Material in South Korea

Fineline Cube Aug 13, 2026
Company Deals

CSPC Pharmaceutical Receives $30 Million Upfront From AstraZeneca Under siRNA Drug Discovery Partnership

Fineline Cube Aug 13, 2026
Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Fineline Cube Aug 12, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Hengrui Pharma’s SHR-7590 Injection Wins NMPA Clinical Trial Approval for Ulcerative Colitis and Crohn’s Disease

Fineline Cube Aug 13, 2026
Company Drug

IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform

Fineline Cube Aug 13, 2026
Company Drug

InnoCare Announces First Patient Dosing of ICP‑B794, a Novel B7‑H3 Targeting ADC

Fineline Cube Oct 30, 2025

China‑based InnoCare Pharma Limited (SHA: 688428, HKG: 9969) today disclosed that its self‑developed antibody‑drug conjugate...

Policy / Regulatory

National Health Commission Unveils Fourth Drug List for Generic Development

Fineline Cube Oct 30, 2025

The National Health Commission (NHC) today released its fourth catalogue of medicines earmarked for generic...

Company

BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition

Fineline Cube Oct 30, 2025

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced during its third‑quarter earnings call that it no longer...

Company

GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth

Fineline Cube Oct 29, 2025

UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) delivered a compelling Q3 2025 earnings report that...

Company Drug

Sihuan Pharmaceutical Secures Fast‑Track Designation for NG‑350A in U.S. Rectal Cancer Treatment

Fineline Cube Oct 29, 2025

Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced today that NG‑350A, a clinical‑stage oncolytic immunotherapy...

Company Legal / IP

YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China

Fineline Cube Oct 29, 2025

Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced today that its high‑concentration antibody formulation for...

Company Deals

BioRay Pharmaceutical Co., Ltd. Signs MENA‑Wide Licensing Deal With Saudi Tabuk Pharmaceutical Manufacturing

Fineline Cube Oct 29, 2025

BioRay Pharmaceutical Co., Ltd. today announced the execution of a comprehensive license, supply, and commercialization...

Company Deals

IASO Biotherapeutics Partners with GC Cell to Advance Equecabtagene Autoleucel CAR‑T Therapy in South Korea

Fineline Cube Oct 29, 2025

IASO Biotherapeutics, a China‑based biotherapeutics developer, today announced a strategic collaboration agreement with GC Cell...

Company Deals

GSK Secures Worldwide Exclusive Rights to Empirico’s EMP‑012, a First‑in‑Class siRNA for COPD

Fineline Cube Oct 29, 2025

GlaxoSmithKline plc (GSK, NYSE: GSK) and Empirico Ltd. today announced a global exclusive licence agreement...

Company Deals

WuXi AppTec Signs Dual MoUs with NEOM and Saudi Ministry of Health to Advance Localized Drug Development

Fineline Cube Oct 29, 2025

WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359) today announced the signing of strategic Memoranda of...

Company Deals

Qyuns Therapeutics Partners with Roche for Global Rights to Long‑Acting Bispecific Antibody QX031N

Fineline Cube Oct 29, 2025

Qyuns Therapeutics Co., Ltd. (HKG: 2509) today announced a global exclusive collaboration and licensing agreement with F. Hoffmann‑La...

Company Drug

Jiangsu Aidea Secures Approval to Launch ADC118 Tablets in China, First Domestic HIV Integrase FDC

Fineline Cube Oct 29, 2025

Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) announced today that its self‑developed Class 1 anti‑HIV drug, ADC118...

Company

Fosun Pharmaceutical Q3 2025 Revenue Slips 5.5% Amid VBP, Innovative Drugs Grow 18%

Fineline Cube Oct 29, 2025

Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today released its third‑quarter 2025 financial results....

Company

Junshi Biosciences Q3 2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA

Fineline Cube Oct 29, 2025

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877,  SHA: 688180) today released its third‑quarter 2025 financial results....

Company Deals

Fosun Pharmaceutical Announces Spin‑Off and HK Listing of Adgenvax

Fineline Cube Oct 29, 2025

Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today disclosed its intention to spin‑off...

Company Deals

Fosun Pharma Target Fund Launches with RMB 1 Billion Capital, Led by China Resources GP

Fineline Cube Oct 29, 2025

Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that its controlled subsidiary,...

Company Drug

Alphamab Oncology Secures FDA Fast‑Track Designation for HER2 Bispecific ADC JSKN003 in Platinum‑Resistant Ovarian Cancer

Fineline Cube Oct 28, 2025

China‑based Alphamab Oncology (HKG: 9966) announced today that the U.S. Food and Drug Administration (FDA)...

Policy / Regulatory

SSY Group Limited Projected to Win 12 Products in China’s Eleventh VBP Round

Fineline Cube Oct 28, 2025

China‑based SSY Group Limited (HKG: 2005) announced today that it has been pre‑selected as the...

Company Drug

Hengrui Pharmaceuticals Secures NMPA Acceptance for Fluzoparib in First‑Line Therapy of DNA‑Repair‑Defect Positive mCRPC

Fineline Cube Oct 28, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that the China National...

Company Drug

Nanjing Leads Biolabs Announces First‑Patient Dose of LBL‑024, a Novel Bispecific Antibody for Biliary Tract Cancer

Fineline Cube Oct 28, 2025

China‑based Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced today that the first patient has...

Posts pagination

1 … 129 130 131 … 708

Recent updates

  • Hengrui Pharma’s SHR-7590 Injection Wins NMPA Clinical Trial Approval for Ulcerative Colitis and Crohn’s Disease
  • Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China
  • IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform
  • Akeso’s Ivonescimab Wins NMPA Approval for First-Line Advanced Squamous Non-Small Cell Lung Cancer in Combination With Chemotherapy
  • Allist Pharmaceuticals Secures Exclusive Greater China License for ArriVent’s Bispecific ADC AST12608/ARR-002
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharma’s SHR-7590 Injection Wins NMPA Clinical Trial Approval for Ulcerative Colitis and Crohn’s Disease

Company Deals

Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China

Company Drug

IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform

Company Drug

Akeso’s Ivonescimab Wins NMPA Approval for First-Line Advanced Squamous Non-Small Cell Lung Cancer in Combination With Chemotherapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.